Symposium Supporters

We are very grateful to the following supporters of the 28th International Symposium on ALS/MND, to be held in Boston, USA on 8 – 10 December 2017. A full list of sponsors will be added in due course.

Platinum sponsor

Cytokinetics is a late-stage biopharmaceutical company focussed on discovering, developing and commercialising first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to increase muscle function and contractility.


Gold sponsors

Through cutting-edge science, Biogen discovers, develops and delivers to patients worldwide therapies for the treatment of neurodegenerative and rare diseases.


Mitsubishi Tanabe Pharma America (MTPA) is dedicated to delivering innovative products that address the unmet medical needs of patients facing serious and life-threatening diseases, including ALS. Based in Jersey City, N.J., MTPA is a wholly-owned subsidiary of Mitsubishi Tanabe Pharma Corporation, the world’s second oldest pharmaceutical company with more than 300 years of experience advancing innovative treatments. In 2017, MTPA introduced in the U.S. the first new treatment option for ALS approved by the FDA in more than 20 years.


PatientsLikeMe is a network and real-time research platform that helps patients connect with others who have the same disease or condition and track and share their own experiences. In the process, they generate data about the real-world nature of disease that help researchers, pharmaceutical companies, regulators, providers and nonprofits develop more effective products, services and care. More than 400,000 patients with 2,500+ conditions are already using PatientsLikeMe to share their experiences. They currently have over 10,000 ALS member profiles.


Silver sponsors

Biohaven is a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates that target neurological diseases, including rare disorders such as spinocerebellar ataxia and ALS. Biohaven’s lead development programs include multiple compounds across its CGRP receptor antagonist and glutamate modulation platforms. The company’s common shares are listed on the NYSE and traded under the ticker symbol BHVN.